Key result
Catheter ablation cuts major events ~22% vs antiarrhythmic drugs in ischemic cardiomyopathy.
Why the study?
The choice between catheter ablation and anti-arrhythmic drugs in the management of ventricular tachycardia episodes in ischemic cardiomyopathy remains challenging.
Does catheter ablation reduce the composite of death, appropriate ICD shocks, VT storm, or cardiac hospitalizations in patients with ventricular tachycardia and ischemic cardiomyopathy compared to antiarrhythmic drugs?
Population
866 patients with VT and ischemic cardiomyopathy across 4 RCTs
Comparison
Catheter ablation vs antiarrhythmic drugs
Design
Systematic review and meta-analysis of randomized controlled trials
Follow-up
Ranging from 24 to 51.6
Authors
Loading...
Favors catheter ablation over antiarrhythmic drugs to lower composite events in ischemic cardiomyopathy VT; reinforces pooled RCT evidence.
Does catheter ablation reduce the composite of death, appropriate ICD shocks, VT storm, or cardiac hospitalizations in patients with ventricular tachycardia and ischemic cardiomyopathy compared to antiarrhythmic drugs?
In patients with ventricular tachycardia and ischemic cardiomyopathy, catheter ablation reduces the composite risk of death, appropriate ICD shocks, VT storm, or cardiac hospitalizations compared to antiarrhythmic drugs.
Abraham et al. (2025) studied this question. Catheter ablation reduced the composite outcome of death, ICD shocks, VT storm, or cardiac hospitalizations by 22% vs antiarrhythmic drugs in ischemic cardiomyopathy (RR 0.78, p=0.032).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: